Fact CheckerSign in

NCT07146542Not yet recruiting

Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia

Source: ClinicalTrials.gov · Last updated 28 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this study is to understand how the protein CD81 affects myeloid leukemia (especially AML) and whether it can help predict patient outcomes or guide treatment. The main question it aims to answer: Is high CD81 expression in myeloid leukemia cells linked to more aggressive disease, poorer treatment response, or shorter survival in patients? Participants: * Newly diagnosed myeloid leukemia patients (primary focus on AML) * Bone marrow or blood samples will be collected during routine diagnostic procedures

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
66 (estimated)
First submitted
21 Aug 2025
Start date
1 Oct 2025
Primary completion date
Mar 2028
Lead sponsor
Assiut University
NCT number
NCT07146542

What you commit to

  • Study type: Observational
  • Planned participants: 66
  • From 1 Oct 2025 to the primary completion date, Mar 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • . Patients with other haematological neoplasms (ALL,CLL, plasma cell myeloma, etc)
    • Patients under any therapeutic intervention
    • Patients with current or previous other malignancies at time of diagnosis

Who the study is looking for

  • 1\. Myeloid leukemia patients 2. Patients of both genders (Males and females) at any age 3. Cases are de novo (Not on treatment)

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.